BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 32448669)

  • 21. Basiliximab is associated with a lower incidence of De novo donor-specific HLA antibodies in kidney transplant recipients: A single-center experience.
    Jarmi T; Abdelmoneim Y; Li Z; Jebrini A; Elrefaei M
    Transpl Immunol; 2023 Apr; 77():101778. PubMed ID: 36584928
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rabbit antithymocyte globulin induction therapy in adult renal transplantation.
    Hardinger KL
    Pharmacotherapy; 2006 Dec; 26(12):1771-83. PubMed ID: 17125438
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Low-dose rabbit anti-thymoglobin globulin versus basiliximab for induction therapy in kidney transplantation.
    Patel HV; Kute VB; Vanikar AV; Shah PR; Gumber MR; Engineer DP; Trivedi HL
    Saudi J Kidney Dis Transpl; 2014 Jul; 25(4):819-22. PubMed ID: 24969194
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of Antithymocyte Globulin, Basiliximab, and Induction-Free Treatment in Living Donor Kidney Transplant Recipients on Tacrolimus-Based Immunosuppression.
    Sonmez O; Ozcan SG; Karaca C; Atli Z; Dincer MT; Trabulus S; Seyahi N
    Exp Clin Transplant; 2024 Apr; 22(4):270-276. PubMed ID: 38742317
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rabbit-ATG or basiliximab induction for rapid steroid withdrawal after renal transplantation (Harmony): an open-label, multicentre, randomised controlled trial.
    Thomusch O; Wiesener M; Opgenoorth M; Pascher A; Woitas RP; Witzke O; Jaenigen B; Rentsch M; Wolters H; Rath T; Cingöz T; Benck U; Banas B; Hugo C
    Lancet; 2016 Dec; 388(10063):3006-3016. PubMed ID: 27871759
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Thymoglobulin Versus Basiliximab Induction Therapy in Low-Risk Kidney Transplant Recipients: A Single-Center Experience.
    Lee H; Lee S; Jeon JS; Kwon SH; Noh H; Han DC; Yun S; Song D
    Transplant Proc; 2018 Jun; 50(5):1285-1288. PubMed ID: 29880348
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of clinical outcome of low-dose and high-dose rabbit antithymocyte globulin induction therapy in renal transplantation: a single-center experience.
    Yang JW; Wang JN; Men TY; Zhang XM; Li XD; Shen B; Li GY; Chen DD
    Ann Transplant; 2014 Jun; 19():277-82. PubMed ID: 24906405
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Improved efficacy of basiliximab over antilymphocyte globulin induction therapy in paediatric renal transplantation.
    Clark G; Walsh G; Deshpande P; Koffman G
    Nephrol Dial Transplant; 2002 Jul; 17(7):1304-9. PubMed ID: 12105256
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The influence of the antithymocyte globulin dose on clinical outcomes of patients undergoing kidney retransplantation.
    Linhares K; Taddeo JB; Cristelli MP; Proença H; Ficher KN; de Marco R; Gerbase-DeLima M; Medina-Pestana J; Tedesco-Silva H
    PLoS One; 2021; 16(5):e0251384. PubMed ID: 33979389
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and efficacy of induction treatment with low thymoglobulin doses in kidney transplantation from expanded-criteria donors.
    Sancho Calabuig A; Gavela Martínez E; Kanter Berga J; Beltrán Calatán S; Avila Bernabeu AI; Pallardó Mateu LM
    Transplant Proc; 2015; 47(1):50-3. PubMed ID: 25645768
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessment of immunosuppression induction with basiliximab compared to antithymocyte-globulin in adult heart transplant patients.
    Eberhardt TE; Kim DH; Nethersole S; Pearson GJ
    Clin Transplant; 2024 Jun; 38(6):e15332. PubMed ID: 38804609
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Basiliximab versus rabbit anti-thymocyte globulin for induction therapy in patients after heart transplantation.
    Flaman F; Zieroth S; Rao V; Ross H; Delgado DH
    J Heart Lung Transplant; 2006 Nov; 25(11):1358-62. PubMed ID: 17097501
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 5-year results of a prospective, randomized, single-center study of alemtuzumab compared with rabbit antithymocyte globulin induction in simultaneous kidney-pancreas transplantation.
    Stratta RJ; Rogers J; Orlando G; Farooq U; Al-Shraideh Y; Farney AC
    Transplant Proc; 2014; 46(6):1928-31. PubMed ID: 25131073
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Induction therapy in renal transplant recipients: how convincing is the current evidence?
    Wagner SJ; Brennan DC
    Drugs; 2012 Mar; 72(5):671-83. PubMed ID: 22439670
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Different impact of rATG induction on CMV infection risk in D+R- and R+ KTRs.
    Kaminski H; Jarque M; Halfon M; Taton B; Di Ascia L; Pfirmann P; Visentin J; Garrigue I; Déchanet-Merville J; Moreau JF; Crespo E; Montero N; Melilli E; Meneghini M; Pascual M; Couzi L; Manuel O; Bestard O; Merville P
    J Infect Dis; 2019 Jul; 220(5):761-771. PubMed ID: 31157865
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Induction immunosuppression improves long-term graft and patient outcome in organ transplantation: an analysis of United Network for Organ Sharing registry data.
    Cai J; Terasaki PI
    Transplantation; 2010 Dec; 90(12):1511-5. PubMed ID: 21057388
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk Factors of Cytomegalovirus Disease in Kidney Transplant Recipients: A Single-Center Study in Thailand.
    Chiasakul T; Townamchai N; Jutivorakool K; Chancharoenthana W; Thongprayoon C; Watanatorn S; Avihingsanon Y; Praditpornsilpa K; Srisawat N
    Transplant Proc; 2015 Oct; 47(8):2460-4. PubMed ID: 26518951
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Increased risk of rejection after basiliximab induction in sensitized kidney transplant recipients without pre-existing donor-specific antibodies - a retrospective study.
    Goumard A; Sautenet B; Bailly E; Miquelestorena-Standley E; Proust B; Longuet H; Binet L; Baron C; Halimi JM; Büchler M; Gatault P
    Transpl Int; 2019 Aug; 32(8):820-830. PubMed ID: 30903722
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of induction therapy on established CMV specific T cell immunity in living donor kidney transplantation.
    Stranavova L; Hruba P; Girmanova E; Tycova I; Slavcev A; Fronek J; Slatinska J; Reinke P; Volk HD; Viklicky O
    Physiol Res; 2018 May; 67(2):251-260. PubMed ID: 29303612
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-thymocyte globulin versus basiliximab induction in renal transplant recipients: Long-term outcome.
    Kesiraju S; Paritala P; Rao Ch UM; Athmakuri SM; Reddy VS; Sahariah S
    Saudi J Kidney Dis Transpl; 2014 Jan; 25(1):9-15. PubMed ID: 24434376
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.